Conventional steroid MR antagonists, including spironolactone and eplerenone, exhibit effectiveness for managing heart failure but are usually accompanied by a heightened risk of hyperkalemia and kidney injury, precluding their administration to individuals with CKD [5]. The gene discussed is NR3C2; the disease is Hyperkalemia.